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What difference does it make? A comparison of health state preferences elicited from 




Objectives: A major debate in the Quality-Adjusted Life-Year (QALY) literature concerns 
whose preferences should be used to estimate health st te values (HSVs) and to calculate 
QALYs. This study explores differences between public and patient values for multiple 
sclerosis (MS) health states, described using an MS-specific classification system (MSIS-
8D). 
 
Methods: The MSIS-8D is an existing preference-based measur of health-related quality of 
life in MS, which has two tariffs of HSVs, based on the preferences of a representative 
sample of the UK general population (n=1702) and of people with MS living in the UK 
(n=1635), elicited using the time trade-off technique.  Here we explore differences between 
HSVs by sample type, using descriptive statistics and multivariate regression methods.   
 
Results:  Overall, the survey of people with MS produced signif cantly higher HSVs; 
estimated values ranged from 0.079-0.883 for the gen ral population survey, and 0.138-0.894 
for the MS survey. Differences in HSVs were more pronounced for severe health states.  The 
difference between patient and public values varied across the dimensions of the MSIS-8D.  
People with MS placed greater importance on C gnition than the general population, leading 
to lower HSVs when impairment was at a worse level; the reverse was true for the Daily 




Conclusions:   We identified significant differences in HSVs by sample type. Using patient 
rather than public values may influence the results of economic evaluations, depending upon 
the dimensions of health-related quality of life affected by the intervention being assessed, 






What is already known about the topic? 
Previous research has shown that preferences elicited from members of the general 
population frequently differ from those of patients for the same health states. However, 
comparisons between population and patient preferenc s have typically relied upon small 
samples of respondents and health states, limiting their ability to examine these differences in 
detail. 
 
What does the paper add to existing knowledge? 
This paper compares two full tariffs of health state values for the same condition-specific 
preference-based measure (the MSIS-8D): one based on the preferences of a representative 
sample of the UK general population and one from a representative sample of people with 
MS. 
Analysis provides a detailed examination of the differences between these two groups in 
terms of the relative importance of individual dimensions of health-related quality of life and 
the impact of moving between levels on each dimension. 
 
What insights does the paper provide for informing health care-related decision making? 
Insights are provided into how the choice of sample for a preference elicitation survey may 







Decisions on the funding of healthcare interventions are frequently informed by evidence 
concerning their cost-effectiveness. Cost-effectiveness is commonly expressed as the cost-
per-QALY, or quality-adjusted life-year, of the intervention [1]. QALYs assess both length 
and quality of life as a single measure, with length of life adjusted by a weight to reflect the 
quality of life during this time. These quality of life (QALY) weights, or health state values 
(HSVs), are usually estimated from preferences given from samples of the general 
population, but they have also been estimated from sa ples of people who have the condition 
that the treatment is designed to address (‘patients’) [2, 3]. 
 
In publicly funded healthcare systems, it is often argued that societal preferences should 
guide resource allocation in order to reflect the views of those who are funding the service. 
Conversely, the theory of welfare economics posits that the well-being of a society equals the 
sum of the utilities of its individual members, implying that it is more appropriate to base 
decisions regarding public programmes on the preferences of those set to gain or lose directly 
from the decision, ie patients. Furthermore, patients are likely to have more experience of 
poor health and may be considered better placed to value how this affects quality of life [3]. 
These considerations have led to suggestions that public preferences may be more suitable for 
system-wide decision-making, while patient values should be used to inform condition-
specific resource allocation and individual-level tr atment decisions [4]. 
 
A number of studies have compared preferences elicited from patients with preferences 
elicited from the general population for the same health states. Significant differences have 
been found, with most studies reporting that patients provide higher HSVs compared to the 
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general population [5-12]. A higher HSV implies that the health state is more preferred, and 
is associated with better health-related quality of life (HRQL). Several reasons have been put 
forward to explain this phenomenon. For example it has been suggested that patients provide 
higher values as a result of scale recalibration [13], which occurs when a person’s 
interpretation of a scale alters in line with changes in their own internal reference point. This 
may occur due to experience of ill health, aging, changes in social comparators or other 
changes in circumstances [3]. Another possible reason is the ability of patients to 
contextualise health state descriptions. The brief, standardised nature of these descriptions 
may be insufficient to fully convey the experience of inhabiting a health state, and patients 
may be more capable of filling in the gaps in these descriptions on the basis of their 
knowledge or experience [7, 14]. Frequently, the additional dimensions of well-being that 
patients consider when valuing a health state are not adversely affected by the disease [15]. 
Conversely, members of the public are likely to experience framing effects, in which the 
framing of health state scenarios around specific dimensions highlights the presence of 
decrements in those dimensions in the absence of a wider context [16]. Another potential 
cause is that healthy people may underestimate the xtent to which they would adapt to 
negative changes in their health. Patients are more likely to have experienced adaptation to 
poor health states, and will take this into account in their preferences [17]. 
 
Studies focusing on mental health [18-21] or dementia [22] health states, however, have 
found that patients provided lower HSVs compared to the general population, and some 
research indicates that the relative importance of particular dimensions of HRQL may differ 
[12, 18, 23]. Furthermore, differences between patient and public values can vary according 
to the severity of the health state, with patients providing lower values for the mildest health 
states and higher values for the most severe states [6, 19-22, 24], resulting in “valuation 
7 
 
compression”, ie a narrower range of HSVs [25]. . Taken together, these differences can have 
sufficient impact on the results of cost-effectiveness studies to influence resource allocation 
decisions, and the direction and nature of their effects can vary [3].  Despite the salience of 
the issue, the debate over whether public or patient preferences should be used to value health 
states has yet to be resolved [26]. 
 
The scope of previous studies has been somewhat limited, comparing directly observed 
valuations of a subset of health states, elicited from relatively small samples of patients and 
the general population. In previous research, the Multiple Sclerosis Impact Scale – Eight 
Dimensions (MSIS-8D) was developed. The MSIS-8D is a preference-based measure for 
multiple sclerosis (MS), which has two sets of HSVs that can be used to inform cost-
effectiveness analysis: one based on the preferences of the general population [27] and one on 
the preferences of people with MS [28]. MS is a long-term neurological condition, which 
frequently follows a relapsing-remitting course butcan be progressive from outset, and 
causes a wide and variable range of physical, psychological and cognitive symptoms [29]. 
Little is known about how the preferences of the general public may differ from those of 
people with MS.  
 
This research aims to compare the two full tariffs o  values that were estimated for the MSIS-
8D and to consider what implications any differences b tween these HSVs may have for 
resource allocation decisions. On the basis of the literature outlined above, we hypothesise 
that people with MS will value health states more highly, place greater weight on non-










The data used in this study were from two previous valuation surveys, one undertaken with a 
sample of the general population and one with a sample of people with MS [27, 28]. . The 
same methods were used for both surveys, enabling comparisons to be drawn [30]. The 
surveys employed the Measurement and Valuation of Health (MVH) version of the time 
trade-off (TTO) technique to elicit HSVs [31] and were administered via the internet to 
maximise sample size and representativeness [32]. The Supplementary Material provides 
additional detail on sample selection and recruitment, procedures for health states considered 
worse than being dead, issues regarding online administration of the TTO and steps taken to 
enhance data quality. The TTO technique asks respondents to choose between Life B, which 
offers a particular health state for ten years, or Life A, which offers full health for a shorter 
period of time (x). In these questions HSVs are calculated as x/10. The MVH process also 
allows respondents to assign negative values to health st tes they consider worse than being 
dead [33]. Health states were described using the MSIS-8D classification system, which 
represents eight dimensions of importance to the HRQL of people with MS: physical 
functioning, mobility, social activities, daily activities, fatigue, cognitive function, emotional 
well-being and depression [34]. Each dimension has four levels. Preferences were elicited for 
a sample of 169 MSIS-8D health states, selected using the Rasch vignette approach [2] to 
reflect states that are likely to be experienced by people with MS at different levels of 
severity. The health states were stratified into five groups according to severity and selected 
at random to produce blocks of five health states. Each respondent valued one block of five 
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health states, plus the worst MSIS-8D state.   Respondents completed the MSIS-8D 
descriptive system for their own health over the prvious two weeks, and a total raw score 
was calculated as a measure of their current health sta us.  Data were collected on age, 
gender, presence of dependent children in the houseld, and socio-economic status. The 
general population sample was recruited through a market research panel, using quota 
sampling to ensure a representative sample of the UK population. People with MS were 
recruited from the UK MS Register, which has been found to be representative of people with 




Analysis of the extent to which the two sets of HSVs differed was undertaken in two phases. 




The methods used in Phase 1 are similar to those reported by Mulhern et al [36]. Data from 
both surveys were combined into a single dataset. Man HSVs from the two valuation 
surveys were compared using a two-sample, two-sided t-t st.   To explore whether 
differences between patient and public values varied according to the severity of the health 
state [6, 19, 20, 24, 37], separate t- sts were carried out for each of five severity groups 
(constructed previously in order to select balanced sets of states for respondents to value), 




Regression analysis was undertaken, based on the standard model that defines the value of a 
health state as follows [2]: 
hij =  f(β′Xλ∂)+ εij 
i: individual health states  
j: individual respondents 
hij: value for health state i valued by respondent j; 
X: vector of dummy variables for each level λ of dimension ∂, with level λ = 1 as 
baseline; 
β: coefficients on X 
εij: error term.  
 
We adopted a random effects specification, as this was found to be the best performing of the 
models previously considered for estimating HSVs for the MSIS-8D [27, 28]. Two models 
were estimated: 
• Model 1 includes a dummy variable for sample-type (atient or public). 
• Model 2 includes the sample-type variable and significant socio-demographic 
variables.   
 
Model 1 aimed to determine whether the sample-type (general population or people with MS) 
was a significant predictor of HSVs, independently of the levels on the dimensions of the 
MSIS-8D. Model 2 aimed to determine whether the sample-type variable remained 
significant when controlling for differences in soci -demographic characteristics and 
respondents’ own MSIS-8D scores. All variables thatwere found to be significantly 
associated with HSVs in bivariate analysis were included in this model. 
11 
 
Further regression analyses using Model 1 included th  addition of interaction terms between 
each dimension of the MSIS-8D and the sample-type dummy variable, enabling us to explore 
whether differences between patients and the public were statistically significant at an 




In the second phase, we compared the published algorithms, recommended for use in 
generating HSVs for MSIS-8D health states from the perspective of the UK general 
population [27] and people with MS [28]. In each case, one preferred model had been 
selected from a number of candidate models, based on predictive ability. Candidate models 
included individual-level and mean-level ordinary least squares, random effects and random 
effects Tobit specifications [38, 39]. In these prefe red models, where dimension-levels were 
represented by non-significant coefficients, the aff cted levels were merged to produce 
additional versions of the models [40]. The predictive ability of the models was assessed in 
terms of the mean absolute error and the proportion of health states with errors greater than 
0.05 or 0.10 [2]. Here, an “error” is defined as the difference between the observed and the 
predicted value for a health state, hence smaller numbers are preferred. 
 
The sizes of the coefficients were compared to investigate differences in the weighting of 
individual dimensions and in the effect of moving between levels on each dimension, and the 







Comparisons of descriptive data 
 
Data from 1576 members of the general population and 1596 people with MS were included 
in the analysis. Responses from 126 members of the general population nd 39 people with 
MS were excluded for providing inconsistent or illogical responses. The median number of 
observations per health state was 47 for the general population survey and 48 for the survey 
of people with MS. Analysis of data quality is provided in the Supplementary Material. 
 
Table 1 reports socio-demographic data for both samples. Differences between the samples 
reflected known differences between people with MS and the general population in the UK: a 
higher percentage of female respondents [29], a lower proportion of respondents aged 45 
years or under [41], and a lower proportion of respondents in employment [42] in the MS 
sample.  
 
The mean observed values for each health state (Appendix 1) ranged from 0.08 for the worst 
health state to 0.89 for the best when valued by the general population, and from 0.15 to 0.94 
when valued by people with MS.  
 
Phase 1 analysis 
 
The results of the t-tests (Table 2) show a significant difference in the mean HSVs derived 
from the two groups. The overall mean HSV was 0.052 higher when derived from the 





The results of Models 1 and 2 are summarised in Table 3.  Model 1 reflects the expected 
pattern of preferences: as dimension-levels increase, reflecting a greater negative impact on 
health status, HSVs decrease. The coefficient for ‘having MS’ (a variable that distinguishes 
between the public and patient samples) is significant, with a positive effect, indicating that 
people with MS reported higher HSVs for MSIS-8D states. Model 2 shows that older age and 
having dependent children were significant predictors of higher HSVs, while being in a 
“severe” MSIS-8D health state was associated with lower HSVs. Inclusion of these variables 
reduced the size of the coefficient for ‘having MS’ from 0.052 (p<0.001) to 0.042 (p=0.002). 
As there was no significant difference between the samples in the proportion of respondents 
with dependent children, this indicates that part of the difference in HSVs is explained by the 
differences in the age profile of the two samples, and that this is partly offset by the 
differences in health status (Table 1).  
Analysis of the interactions between sample type and dimensions of the MSIS-8D found that 
the differences between patients and the public were not statistically significant at an 
individual dimension level (p>0.05). 
 
Phase 2 analysis 
 
Table 4 compares the preferred models recommended for estimating MSIS-8D values from 
the perspective of the UK general population (the “Public Model”) and of people with MS 




HSVs based on public preferences ranged from 0.079 to 0.882, while those based on the 
preferences of people with MS ranged from 0.138 to 0.893. The MS Model had a slightly 
smaller mean absolute error and fewer health states wi h prediction errors greater than 0.1.  
When health states were valued by people with MS, each increase in problems with 
Cognition (represented by moving from level 1 to the level corresponding to each model 
coefficient) had a greater negative impact on HSVs than when health states were valued by 
the general population. This resulted in larger coeffici nts for each level of the Cognition 
dimension in the MS Model. 
Conversely, when health states were valued by members of the general population, each 
increase in problems with Daily Activities, Fatigue and Depression had a greater negative 
impact on HSVs than when valued by people with MS, resulting in larger coefficients for all 
levels of these dimensions in the Public Model. 
For the remaining dimensions, the differences betwen patients and the public varied between 
levels, with a mix of larger and smaller coefficients. 
 
Table 4 and Figure 2 also illustrate the impact on HSVs of moving between adjacent levels 
on each dimension, ie from level 1 to 2, from level 2 to 3, and from level 3 to 4. Here, the 
differences between people with MS and the general population are represented by the 
differences in the distance between adjacent model coefficients.  This reveals a more complex 
picture, in which most dimensions had a mix of smaller and larger single-level increments 







Discussion of the results 
 
We have found clear differences in HSVs derived using preferences elicited from people with 
MS compared to those of the general public. As hypothesised, the analysis of observed HSVs 
indicates that people with MS valued health states more highly than the general population, ie 
they were prepared to give up less time in full healt  in order to avoid health problems 
associated with MS. This difference was significant cross the full range of severity, although 
it was less pronounced in the mildest health states, suggesting that differences between 
patient and public values vary according to the severity of the health state as anticipated. A 
similar pattern emerged from the regression analysis: the type of sample (general population 
or people with MS) was a significant predictor of HSVs, and the range of predicted values 
was narrower when based on the preferences of people with MS (0.755 compared to 0.803 
for the general population), providing some support for he hypothesis that patient values are 
subject to valuation compression. 
 
The methods used here provide a robust basis for the comparison of two preference elicitation 
surveys for the same classification system, using lar e, representative samples of the UK 
general population and of people with MS. Earlier studies have reported similar findings [5-8, 
10, 12, 19-22, 24]. However, as far as we are aware, this is the first study to estimate full 
tariffs from both perspectives for the same classification system, using a choice-based 
technique. This has enabled us to undertake more detailed analysis of the impact of eliciting 
preferences from these two groups across the full range of dimensions (and levels) of HRQL. 
 
A key advantage of this approach is that it provides the opportunity to investigate whether 
people with MS and members of the general population apply different relative weights to 
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individual dimensions of HRQL.  On the basis of previous research [19-23], we hypothesised 
that people with MS would give greater weight to dimensions associated with mental and 
cognitive health. This hypothesis was only partially supported.  Contrary to expectations, the 
model based on the preferences of the general population had larger coefficients for the 
Depression, Fatigue and Daily Activities dimensions than the model based on the preferences 
of people with MS, indicating that the general population placed greater weight on these 
dimensions. Coefficient sizes were larger when based on the preferences of people with MS 
for the Cognition dimension, reflecting the findings of Rowen and colleagues [22]. Although 
the Phase 1 analysis found no statistically significant differences between the coefficients, the 
size and direction of the differences that were apparent in the Phase 2 analysis may influence 
the apparent cost-effectiveness of interventions that affect these dimensions. For example, 
interventions targeting the impact of MS on cognitive function may appear more cost-
effective if assessed using HSVs based on the preferenc s of people with MS [23]. 
 
For the purposes of economic evaluation, the changes in HSVs that occur when moving 
between health states are more relevant than their absolute size. If all health states were 
valued 0.02 higher by patients, both versions of the model would produce identical values for 
any given change in health status (excluding any impacts from mortality). It is the difference 
in the relative weighting of dimensions and in the eff ct of changes in individual dimension-
levels that is relevant in determining the effects on the results of cost effectiveness analysis.  
For example, a shift from health state 32432222 (level 4 on the Mobility dimension, level 3 
on Physical and Daily Activities, level 2 on all other dimensions) to health state 22322222 
(level 3 on Mobility, level 2 on all other dimensions) produces an improvement in HSV of 
0.05 (0.71 – 0.66) using the model based on public preferences, compared to 0.11 (0.80 – 
0.69) using the model based on the preferences of people with MS. Conversely, a shift from 
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health state 22224222 (level 4 on Fatigue, level 2 on all other dimensions) to health state 
22223221 (level 3 on Fatigue, level 1 on Depression, level 2 on all other dimensions) 
produces an improvement of 0.09 (0.74 – 0.65) using the model based on public preferences, 
compared to 0.04 (0.78 – 0.74) using the model based on the preferences of people with MS. 
Discrepancies of this magnitude in the value of a shift from one health state to another may 
have serious implications for the results of economic evaluations, and could influence 
resource allocation decisions [3]. 
 
Limitations of study 
 
The main limitation of this study is that it is quantitative in nature and therefore cannot 
explain why preferences for health states differ between the general population and people 
with MS. We are currently exploring this, using cognitive interviews. This will help to inform 
the debate regarding whether preferences should be elicit d from patients or from the general 
public when estimating QALY weights for a condition-specific PBM [38]. 
 
In order to achieve large, representative samples of the general population and people with 
MS living across the UK, valuation surveys were administered online. Previous studies have 
shown that the quality of TTO data can suffer in the absence of an interviewer [32, 43-45]. 
Therefore, steps were taken to maximise data quality (see supplementary material). 
 
Part of the difference in HSVs was explained by the diff ring age profiles of the samples: 
overall, the sample of people with MS was older than the general population sample. In both 
surveys, older people valued health states more highly, ie they were less willing to give up 
life-years to avoid suboptimal health states, than younger respondents. This difference in age 
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profile reflects an acknowledged difference between th  two populations[41], hence the 
results still represent a real difference between people with MS and the general population. It 
is, however, possible that the difference in HSVs between age groups was an artefact of the 
valuation technique employed, in which respondents were asked to trade life-years against 
HRQL [12]. This could be investigated by exploring alternative preference elicitation 
techniques, such as the standard gamble, discrete choice experiments, or alternative versions 
of the TTO, using different time horizons. 
 
Possible reasons for differences in values 
 
One of the interesting features of the results is that respondents whose own current health 
status was classified as “severe” provided significantly lower HSVs than other respondents, 
independently of whether they had MS. Given that respondents with MS were more likely to 
be in a “severe” health state (Table 1), this may shed some light on the reasons why patient 
and public values differ. It does not appear to be the differences in the current health status of 
the two groups of respondents that causes people with MS to value health states more highly 
than the general population. Instead, this finding su gests that the causal mechanisms 
underpinning the differences between public and patient values are perhaps more aligned to 
attitudinal differences associated with the experience, and the process, of living with a 
chronic condition such as MS. This is an important finding, which merits further 
investigation beyond the scope of this paper. 
 
Of the suggested mechanisms by which patients value health states more highly, few offer a 
convincing explanation for why the difference between public and patient values is reversed 
for certain dimensions of HRQL. A possible cause relates to differences between individual 
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domains of HRQL in terms of patients’ capacity to adapt to decrements. As Dolan and 
Kahneman [17] have suggested, some health states may be easier to adapt to than others, 
providing a normative argument to support the use of patient preferences to inform resource 
allocation decisions.  However, patient preferences th mselves are not immune to distortions, 
and are prone to value compression, which can reduce the apparent cost-effectiveness of 
interventions. Consequently, Dolan and Kahneman have proposed novel methods for valuing 
health states according to experienced utility, rather han hypothetical preferences. 
Meanwhile, within the current methodological framework, the debate over “whose values” 
should inform resource allocation continues. We recommend using both MSIS-8D and MSIS-
8D-P values within sensitivity analyses, alongside the preferred PBM for a given jurisdiction 
(eg the EQ-5D in the UK), to provide broader, contextual information about the likely cost-





We have shown that, overall, eliciting preferences from people with MS generates higher 
values for MSIS-8D health states than HSVs based on the preferences of the general public. 
Importantly, however, the impact of using patient values on the results of cost-effectiveness 
analyses will vary, depending upon the specific dimensions of HRQL that are affected by the 
intervention being assessed. The choice of “whose preferences” to use could therefore have 
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Female 829 53% 1145 73% 




16 to 25 206 13% 7 0% 
26 to 35 269 17% 85 5% 
36 to 45 261 17% 304 19% 
46 to 55 279 18% 504 32% 
56 to 65 253 16% 463 30% 




No 1148 73% 1091 71% 




Employed 801 51% 633 41% 
Not employed 770 49% 912 59% 
Socio-economic group     
A or B 422 26.78% 900 59.92% 
C1 or C2 790 50.13% 403 26.83% 
D or E 364 23.10% 199 13.25% 
Own MSIS-8D score     
26 
 
Mild 1118 70.94% 442 27.69% 
Moderate 297 18.85% 686 42.98% 
Severe 161 10.22% 468 29.32% 
Diagnosed with MS 9 0.57% 1596 100% 
Socio-economic group is defined according to the Approximated 
Social Grade Categories developed by the UK Office or National 
Statistics. 
Own MSIS-8D scores are calculated as the sum of the raw scores 
over the eight items of the descriptive system. 
Mild MSIS-8D_total score = 8 - 16 
Moderate MSIS-8D_total score = 17 - 24 
Severe MSIS-8D_total score = 25 - 32 
nb Figures may not sum to the total number of respondents due to 






Table 2 Results of t-tests to investigate differences between observed health state values 






Difference t stat p-value 
All health states Mean HSV 0.484 0.536 -0.052 -7.878 <0.001 
 SD 0.467 0.450    
Severity Group 1 Mean HSV 0.817 0.845 -0.027 -3.364 <0.001 
(least severe) SD 0.233 0.224    
Severity Group 2 Mean HSV 0.682 0.739 -0.057 -5.263 <0.001 
 SD 0.319 0.289    
Severity Group 3 Mean HSV 0.578 0.639 -0.061 -4.695 <0.001 
 SD 0.383 0.351    
Severity Group 4 Mean HSV 0.473 0.531 -0.058 -3.953 <0.001 
 SD 0.421 0.398    
Severity Group 5 Mean HSV 0.269 0.318 -0.048 -2.849 0.004 
 SD 0.483 0.474    
Worst health 
state 
Mean HSV 0.083 
0.146 -0.063 -3.699 <0.001 
 SD 0.480 0.480    
Observations for all health states: public = 9,456; people with MS =  9,576; degrees of freedom = 
19030 
Observations for each severity group: public = 1576; people with MS =1596; degrees of freedom 
= 3170 
HSV = health state value 





Table 3 Results of regression analysis for both samples combined, showing significance 
of having MS (Model 1) and of socio-demographic variables (Model 2) 
  
Model 1 Model 2 
Dimension Level Coefficient   p-value Coefficient   p-value 
Physical 2 -0.048 <0.001 -0.049 <0.001 
 
3 -0.052 0.001 -0.056 0.001 
 
4 -0.162 <0.001 -0.164 <0.001 
Social 2 -0.013 0.264 -0.012 0.305 
 
3 -0.031 0.068 -0.032 0.065 
 
4 -0.073 <0.001 -0.077 <0.001 
Mobility 2 -0.012 0.276 -0.012 0.289 
 
3 -0.027 0.096 -0.024 0.151 
 
4 -0.089 <0.001 -0.086 <0.001 
Daily activities 2 -0.013 0.286 -0.011 0.371 
 
3 -0.027 0.106 -0.025 0.136 
 
4 -0.06 0.002 -0.058 0.004 
Fatigue 2 -0.005 0.619 -0.005 0.648 
 
3 -0.017 0.272 -0.015 0.334 
 
4 -0.064 0.001 -0.060 0.002 
Emotion 2 -0.016 0.122 -0.017 0.104 
 
3 -0.042 0.006 -0.042 0.007 
 
4 -0.078 <0.001 -0.081 <0.001 




3 -0.043 0.006 -0.042 0.009 
 
4 -0.103 <0.001 -0.105 <0.001 
Depression 2 -0.012 0.251 -0.016 0.146 
 
3 -0.055 <0.001 -0.057 <0.001 
 
4 -0.149 <0.001 -0.146 <0.001 
Constant 
 
0.861 <0.001 0.753 <0.001 
Demographics      
Having MS 
 
0.052 <0.001 0.042 0.002 
















 Over 65   
  
0.103 <0.001 
Dependent children  Yes   
  
0.065 <0.001 
Employed No    
 
0.015 0.254 




D or E 
  
0.019 0.231 









































Mild MSIS-8D_total score = 8 - 16 
Moderate MSIS-8D_total score = 17 - 24 
Severe MSIS-8D_total score = 25 - 32 
Basecase for socio-demographic variables: age group 18-25; no dependent children, 
employed or self-employed; socio-economic group A or B; MSIS-8D group mild. 
Gender is not included in this analysis because it was not found to be associated with 





Table 4 Differences between the models used to produce tariffs for the MSIS-8D from 
the general public and from people with MS 
  Model coefficients Impact of moving between levels 









Physical 2 -0.053** -0.047** -0.006 1 to 2 0.053 0.047 +0.006 
3 -0.060** -0.065** +0.006 2 to 3 0.006 0.018 -0.012 
4 -0.185** -0.175** -0.010 3 to 4 0.125 0.110 +0.015 
Social 2 0‡ 0‡ 0.000 1 to 2 0.000 0.000 0.000 
3 -0.028* -0.032* +0.004 2 to 3 0.028 0.032 -0.004 
4 -0.079** -0.067** -0.012 3 to 4 0.051 0.036 +0.016 
Mobility 2 -0.022 -0.003 -0.019 1 to 2 0.022 0.003 +0.019 
3 -0.022† -0.003† -0.019 2 to 3 0.000 0.000 0.000 
4 -0.069** -0.077** +0.008 3 to 4 0.047 0.074 -0.027 
Daily 
activities 
2 -0.024 0‡ -0.024 1 to 2 0.024 0.000 +0.024 
3 -0.024† -0.020 -0.004 2 to 3 0.000 0.020 -0.020 
4 -0.064** -0.048* -0.016 3 to 4 0.040 0.028 +0.012 
Fatigue 2 -0.026* 0‡ -0.026 1 to 2 0.026 0.000 +0.026 
3 -0.026† -0.021 -0.005 2 to 3 0.000 0.021 -0.021 
4 -0.088** -0.063** -0.025 3 to 4 0.062 0.042 +0.020 
Emotion 2 0‡ -0.015 +0.015 1 to 2 0.000 0.015 -0.015 
3 -0.041** -0.042* +0.001 2 to 3 0.041 0.026 +0.014 
4 -0.084** -0.069** -0.015 3 to 4 0.044 0.027 +0.016 
Cognition 2 -0.014 -0.027* +0.014 1 to 2 0.014 0.027 -0.014 
3 -0.014† -0.052** +0.038 2 to 3 0.000 0.025 -0.025 
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4 -0.072** -0.116** +0.044 3 to 4 0.058 0.064 -0.006 
Depression 2 -0.029* 0‡ -0.029 1 to 2 0.029 0.000 +0.029 
3 -0.074** -0.040** -0.034 2 to 3 0.045 0.040 +0.005 
4 -0.161** -0.140** -0.022 3 to 4 0.088 0.100 -0.012 
Constant 
 
0.882 0.893 -0.011 
    
Model performance 
Coefficients: 18 19     
   significant (p<0.05) 15 (83.33%) 15 (78.95%) 
   
 
Overall R-squared 0.2951 0.3013     




    
Mean absolute error 0.0414 0.0364 
   
 
Errors > 0.1 11 (6.51%) 3 (1.78%) 
   
 
Errors > 0.05 52 (30.77%) 52 (30.77%) 
   
 
Range of HSVs 0.079 to 0.882  0.138 to 0.893     
Observations (groups) 9456 (1576) 9576 (1596)     
‡levels 1 and 2 merged; †levels 2 and 3 merged; * p<0.05;  **p<0.01 
Diff = difference:  
+ indicates that the size of the coefficient or the impact of moving between levels was greater 
when based on the preferences of people with MS 
- indicates that the size of the coefficient or the impact of moving between levels was smaller 
when based on the preferences of people with MS 
HSV = health state value 
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